These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31781900)

  • 21. Drug-eluting bead transarterial chemoembolization with medium-sized versus small-sized CalliSpheres microspheres in unresectable primary liver cancer.
    Zhang J; Feng GA; Li Y; Wang W
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):388-393. PubMed ID: 34708554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study.
    Wen P; Chen SD; Wang JR; Zeng YH
    Oncol Res; 2019 May; 27(5):583-592. PubMed ID: 31053181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma.
    Bi Y; Shi X; Ren J; Yi M; Han X; Song M
    BMC Gastroenterol; 2021 May; 21(1):231. PubMed ID: 34020608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients.
    Gomes AS; Monteleone PA; Sayre JW; Finn RS; Sadeghi S; Tong MJ; Britten CD; Busuttil RW
    AJR Am J Roentgenol; 2017 Oct; 209(4):722-732. PubMed ID: 28705059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
    BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study.
    Kokabi N; Camacho JC; Xing M; Edalat F; Mittal PK; Kim HS
    J Magn Reson Imaging; 2015 Oct; 42(4):981-9. PubMed ID: 25683022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicentre prospective study of drug-eluting bead chemoembolisation safety using tightly calibrated small microspheres in non-resectable hepatocellular carcinoma.
    Urbano J; Echevarria-Uraga JJ; Ciampi-Dopazo JJ; Sánchez-Corral JA; Cobos Alonso J; Anton-Ladislao A; Peña-Baranda B; Nacarino-Mejias V; González-Costero R; Muñoz Ruiz-Canela JJ; Pérez-Cuesta J; Lanciego C; de Gregorio MA
    Eur J Radiol; 2020 May; 126():108966. PubMed ID: 32278280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conventional versus Doxorubicin-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: a Tertiary Medical Centre Experience in Malaysia.
    Rahman FA; Naidu J; Ngiu CS; Yaakob Y; Mohamed Z; Othman H; Jarmin R; Elias MH; Hamid NA; Mokhtar NM; Ali RR
    Asian Pac J Cancer Prev; 2016; 17(8):4037-41. PubMed ID: 27644658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of treatment response, survival and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres versus conventional transarterial chemoembolization in treating hepatocellular carcinoma.
    Zhao C; Ma SPZCY
    J BUON; 2019; 24(3):1150-1166. PubMed ID: 31424674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Huge Hepatocellular Carcinoma Treated with Radical Hepatectomy after Drug-eluting Bead Transarterial Chemoembolization.
    Fujita M; Okai K; Hayashi M; Abe K; Takahashi A; Kimura T; Kenjo A; Marubashi S; Hashimoto Y; Ohira H
    Intern Med; 2019 Apr; 58(8):1103-1110. PubMed ID: 30626806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health-Related Quality of Life in Patients with Hepatocellular Carcinoma Treated with Initial Transarterial Chemoembolization.
    Hinrichs JB; Hasdemir DB; Nordlohne M; Schweitzer N; Wacker F; Vogel A; Kirstein MM; Marquardt S; Rodt T
    Cardiovasc Intervent Radiol; 2017 Oct; 40(10):1559-1566. PubMed ID: 28488104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transarterial Chemoembolization with Epirubicin-Loaded Microspheres for Hepatocellular Carcinoma: A Prospective, Single-Arm, Multicenter, Phase 2 Study (STOPPER Trial).
    Zhu HD; Li X; Sun JH; Zhu X; Liu ZY; Li HL; Lu J; Yan ZP; Shao GL; He XF; Chao M; Lu LG; Zhong BY; Li R; Zhang Q; Teng GJ
    Cardiovasc Intervent Radiol; 2024 Mar; 47(3):325-336. PubMed ID: 38413420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads.
    Bi Y; Shi X; Ren J; Yi M; Han X
    Sci Rep; 2022 May; 12(1):8136. PubMed ID: 35581365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Drug Eluting Bead TACE with Microspheres <150 μm for the Treatment of Hepatocellular Carcinoma.
    Sattler T; Bredt C; Surwald S; Rust C; Rieger J; Jakobs T
    Anticancer Res; 2018 Feb; 38(2):1025-1032. PubMed ID: 29374736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of CalliSpheres
    Liu Y; Huang W; He M; Lian H; Guo Y; Huang J; Zhou J; Zhu K
    Oncol Res; 2019 May; 27(5):565-573. PubMed ID: 30005719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization.
    Pipa-Muñiz M; Sanmartino S; Mesa A; Álvarez-Navascués C; González-Diéguez ML; Cadahía V; Rodríguez JE; Vega F; Rodríguez M; Costilla-García SM; Varela M
    BMC Gastroenterol; 2020 Jun; 20(1):166. PubMed ID: 32487071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs.
    Megías Vericat JE; García Marcos R; López Briz E; Gómez Muñoz F; Ramos Ruiz J; Martínez Rodrigo JJ; Poveda Andrés JL
    Radiologia; 2015; 57(6):496-504. PubMed ID: 25857250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres
    Sun J; Zhou G; Xie X; Gu W; Huang J; Zhu D; Hu W; Hou Q; Shi C; Li T; Zhang X; Ji W; Ying S; Peng Z; Zhou J; Yu Z; Ji J; Du H; Guo X; Fang J; Han J; Xu H; Sun Z; Yu W; Shao G; Wu X; Hu H; Li L; Zheng J; Luo J; Chen Y; Cao G; Hu T
    Oncol Res; 2020 Feb; 28(1):75-94. PubMed ID: 31558180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
    BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Economic impact of transarterial chemoembolization with drug eluting beads in the treatment of hepatocellular carcinoma].
    Malbranche C; Boulin M; Guiu B; Pernot C; Cercueil JP; Serge Aho L; Musat A; Bedenne L; Hillon P; Guignard MH; Fagnoni P
    Bull Cancer; 2011 Jun; 98(6):671-8. PubMed ID: 21642049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.